Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug aims to reshape bodies in obesity trial

NCT ID NCT07169942

Summary

This study is testing whether an investigational drug called aleniglipron can change body composition—specifically reducing fat mass while preserving muscle—in adults living with obesity. About 71 participants will receive either the drug or a placebo for 40 weeks. The main goal is to see how much total body fat changes, measured by a special X-ray scan.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY, OVERWEIGHT, OR CHRONIC WEIGHT MANAGEMENT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site

    Phoenix, Arizona, 85020, United States

  • Research Site

    Chicago, Illinois, 60602, United States

  • Research Site

    Richfield, Minnesota, 55423, United States

  • Research Site

    City of Saint Peters, Missouri, 63303, United States

  • Research Site

    Rochester, New York, 14609, United States

  • Research Site

    Wilmington, North Carolina, 28401, United States

  • Research Site

    Norman, Oklahoma, 73069, United States

  • Research Site

    Moncks Corner, South Carolina, 29461, United States

  • Research Site

    North Charleston, South Carolina, 29405, United States

  • Research Site

    Austin, Texas, 78704, United States

  • Research Site

    San Antonio, Texas, 78240, United States

Conditions

Explore the condition pages connected to this study.